Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian J. Druker

Showing results (1-10 of 278) with videos related to

Pageof 28
Sort By:
Seminars in Hematology|February 4, 2003
Imatinib alone and in combination for chronic myeloid leukemiaBrian J Druker
Seminars in Hematology|June 5, 2003
Chronic myeloid leukemia in the imatinib eraBrian J Druker
Advances in Cancer Research|August 26, 2004
Imatinib as a paradigm of targeted therapiesBrian J Druker
Trends in Molecular Medicine|April 3, 2002
STI571 (Gleevec) as a paradigm for cancer therapyBrian J Druker
Cell Cycle (Georgetown, Tex.)|July 16, 2004
Imatinib: paradigm or anomaly?Brian J Druker
Blood|December 10, 2008
Translation of the Philadelphia chromosome into therapy for CMLBrian J Druker
Cancer Cell|June 28, 2002
Perspectives on the development of a molecularly targeted agentBrian J Druker
Expert Opinion on Pharmacotherapy|June 5, 2003
Imatinib mesylate in the treatment of chronic myeloid leukaemiaBrian J Druker
European Journal of Cancer (Oxford, England : 1990)|January 17, 2003
Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapyBrian J Druker
The Journal of Clinical Investigation|August 3, 2007
Applying the discovery of the Philadelphia chromosomeDaniel W Sherbenou, Brian J Druker
Pageof 28

Showing results (1-10 of 278) with videos related to

Sort By:
Pageof 28
Seminars in Hematology|February 4, 2003
Imatinib alone and in combination for chronic myeloid leukemiaBrian J Druker
Seminars in Hematology|June 5, 2003
Chronic myeloid leukemia in the imatinib eraBrian J Druker
Advances in Cancer Research|August 26, 2004
Imatinib as a paradigm of targeted therapiesBrian J Druker
Trends in Molecular Medicine|April 3, 2002
STI571 (Gleevec) as a paradigm for cancer therapyBrian J Druker
Cell Cycle (Georgetown, Tex.)|July 16, 2004
Imatinib: paradigm or anomaly?Brian J Druker
Blood|December 10, 2008
Translation of the Philadelphia chromosome into therapy for CMLBrian J Druker
Cancer Cell|June 28, 2002
Perspectives on the development of a molecularly targeted agentBrian J Druker
Expert Opinion on Pharmacotherapy|June 5, 2003
Imatinib mesylate in the treatment of chronic myeloid leukaemiaBrian J Druker
European Journal of Cancer (Oxford, England : 1990)|January 17, 2003
Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapyBrian J Druker
The Journal of Clinical Investigation|August 3, 2007
Applying the discovery of the Philadelphia chromosomeDaniel W Sherbenou, Brian J Druker
Pageof 28